Navigation Links
FDA Announces New Safety Recommendations for High-Dose Simvastatin
Date:6/8/2011

d analyses of adverse events submitted to the FDA's Adverse Event Reporting System. All showed that patients taking simvastatin 80 mg daily had an increased risk of muscle injury compared to patients taking lower doses of simvastatin or other statin drugs. The risk of muscle injury is highest during the first year of treatment with the 80 mg dose of simvastatin, is often the result of interactions with certain other medicines, and is frequently associated with a genetic predisposition for simvastatin-related muscle injury.

Simvastatin is sold under the brand-name Zocor and as a single-ingredient generic product. It is also sold in combination with ezetimibe as Vytorin and in combination with niacin as Simcor.

The FDA has revised the drug labels for simvastatin and Vytorin to include the new 80 mg dosing restrictions. The agency also revised the labels for simvastatin, Vytorin and Simcor to include new dosing recommendations when these drugs are used with certain medications that interact to increase the level of simvastatin in the body, which can increase the risk for myopathy. Patients who are unable to adequately lower their level of LDL-C on simvastatin 40 mg should not be given the higher 80 mg dose of simvastatin;  instead, they should be placed on an alternative LDL-C-lowering treatment(s).

For more information:

FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury
http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm

Previous FDA Drug Safety Communication: Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
2. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
3. Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure
4. Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
5. Grifols Announces Combined Operations With Talecris to Begin a New Era as a Global Leader of Life-Saving Plasma Therapeutics
6. Edison Pharmaceuticals Announces FDA Grants EPI-743 Orphan Drug Designation
7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Invalidity of J&J Patents
8. Alere Inc. Announces Extension of Consent Solicitations Related to its 9.0% Senior Subordinated Notes Due 2016, 8.625% Senior Subordinated Notes Due 2018 and 7.875% Senior Notes Due 2016 and Increased Consent Fees
9. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
10. Topaz Pharmaceuticals Announces New Drug Application for the Treatment of Head Lice Accepted by FDA
11. Ore Pharmaceutical Holdings Announces Name Change and Reverse/Forward Stock Split to be Effective June 10, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... ST. LOUIS , Oct. 1, 2014  Express ... its two nationally available 2015 Express Scripts Medicare ® ... retail pharmacy network featuring Walgreens (NYSE: WAG ... obtain more value, choice and clinical support  for their ... the Express Scripts Medicare Value or ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal Philips ... today announced its eCareCoordinator and eCareCompanion telehealth applications ... and Drug Administration (FDA). A part of Philips ... , eCareCoordinator and eCareCompanion are focused on patient ... clinical applications to be available through the cloud-based ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... MASI ) announced today that it will release first ... the market closes on May 2, 2012. The conference call to ... ET) and will be hosted by Joe Kiani, Chairman and Chief ... Chief Financial Officer. A live webcast of the conference ...
... 2012 Financial executives in the medical device manufacturing ... burden of its related compliance costs will have a ... a survey conducted by KPMG LLP, the audit, tax ... companies are already contemplating actions such as price increases ...
Cached Medicine Technology:Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2 2Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2 3KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... 2014 Farmington Company today announced ... mission and visual identity helping brokers, consultants and ... them to create greater benefit communication synergies. They ... on empowering customers to better leverage Farmington Company’s ... jewel of the rebrand is the refreshed tagline: ...
(Date:10/1/2014)... Hills, California (PRWEB) October 01, 2014 ... expert, Dr. Kathleen Mojas is celebrating 20 years of ... has assisted hundreds of people to achieve greater joy ... an important list of warning signs and suggestions for ... , Dr. Mojas explains: “Believe it or not, ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... Canadian study finds increase in non-serious side effects , , ... compounds called cannabinoids from the marijuana plant don,t increase ... with an increase in some non-serious side effects, Canadian ... Montreal and the University of British Columbia (UBC) examined ...
... introduces its Contract Research Development as an invaluable resource to medical ... ... 2008 -- Zeus, Inc. introduced its Contract Research Development at the ... the Jacob K. Javits Convention Center in New York. Showcasing ...
... its wholly-owned subsidiary Embryome Sciences, Inc. announced ... International Embryome Initiative, an international collaboration with ... first systematic map of all the cell ... In a paper published today titled “The ...
... /PRNewswire-FirstCall/,-- Schering-Plough Corp. (NYSE: SGP ) and ... the withdrawal of the New Drug Application (NDA) ... terminated the Schering-Plough/Merck Pharmaceuticals,respiratory joint venture, which was ... fixed-combination product that would combine loratadine and,montelukast. This ...
... augment MDS Analytical Technologies, cellular ... ... /PRNewswire-FirstCall/ - MDS Analytical,Technologies, a leader in innovative solutions ... has acquired California-based,Blueshift Biotechnologies (Sunnyvale, CA) for $13 million. ...
... Clinical Development Program Investigating Golimumab in the ... Basis for the Application, HORSHAM, Pa., June ... License Application (BLA) has been submitted to the ... of golimumab,(CNTO 148) as a monthly subcutaneous treatment ...
Cached Medicine News:Health News:Drugs With Marijuana Compounds Don't Boost Adverse Events 2Health News:Contract Research Development Debuts at MD&M Touting Expertise, Innovation and Collaboration 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 2Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 3Health News: BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative 4Health News:MDS Analytical Technologies Acquires Blueshift Biotechnologies 2Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4Health News:Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: